» Articles » PMID: 24630337

In-hospital and 1-year Outcomes of Acute Heart Failure Patients According to Presentation (de Novo Vs. Worsening) and Ejection Fraction. Results from IN-HF Outcome Registry

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2014 Mar 18
PMID 24630337
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To investigate the outcomes of hospitalized patients with both de-novo and worsening heart failure (HF) with preserved left ventricular ejection fraction (LVEF) (HFpEF) (LVEF ≥ 50%), compared to those with reduced LVEF (HFrEF).

Methods And Results: We studied 1669 patients (22.6% HFpEF) hospitalized for acute HF in the prospective multi-center nationwide Italian Network on Heart Failure (IN-HF) Outcome Registry. In all patients LVEF was assessed during hospitalization. De-novo HF presentations constituted 49.6% of HFpEF and 43.1% of HFrEF hospitalizations. All-cause mortality during hospitalization was lower in HFpEF than HFrEF (2.9% vs 6.5%, p=0.01), but this mortality difference was not significant at 1 year (19.6% vs 24.4%, p=0.06), even after adjusting for clinical covariates. Similarly, there were no differences in 1-year mortality between HFpEF and HFrEF when compared by cause of death (cardiovascular vs non-cardiovascular) or mode of presentation (worsening HF vs de novo). Rehospitalization rates (all-cause, non-cardiovascular, cardiovascular, HF-related) at 90 days and 1 year were also similar. Mode of presentation influenced rehospitalizations in HFpEF, where those presenting with worsening HFpEF had higher all-cause (36.8% vs 21.6%, p=0.001), cardiovascular (28.1% vs 14.9%, p=0.002), and HF-related (21.1% vs 7.7%, p=0.0003) rehospitalization rates at 1 year compared to those with de novo presentations.

Conclusions: Outcomes at 1 year following hospitalization for HFpEF are as poor as that of HFrEF. A prior history of HF decompensation or hospitalization identifies patients with HFpEF at particularly high risk of recurrent events. These findings may have implications for clinical practice, quality and process improvements and trial design.

Citing Articles

Timing of acute decompensated heart failure in patients with heart failure and mildly reduced ejection fraction.

Steffen H, Abel N, Lau F, Schmitt A, Reinhardt M, Akin M Heart Vessels. 2025; .

PMID: 39841200 DOI: 10.1007/s00380-024-02505-3.


Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III....

Lund L, Crespo-Leiro M, Laroche C, Zaliaduonyte D, Saad A, Fonseca C Eur J Heart Fail. 2024; 26(12):2487-2501.

PMID: 39257278 PMC: 11683873. DOI: 10.1002/ejhf.3445.


Heart failure with preserved ejection fraction.

Hamo C, DeJong C, Hartshorne-Evans N, Lund L, Shah S, Solomon S Nat Rev Dis Primers. 2024; 10(1):55.

PMID: 39143132 DOI: 10.1038/s41572-024-00540-y.


Thiol/Disulfide Homeostasis: A New Oxidative Marker in Heart Failure Patients with Preserved Ejection Fraction.

Turinay Ertop Z, Aslan A, Neselioglu S, Durmaz T Anatol J Cardiol. 2024; .

PMID: 38994629 PMC: 11317786. DOI: 10.14744/AnatolJCardiol.2024.4187.


Real-World Clinical Burden of Newly Diagnosed Heart failure in Thai Patients.

Boonyapiphat T, Tangkittikasem T, Torpongpun A, Senthong V, Jiampo P Cardiol Ther. 2024; 13(2):415-430.

PMID: 38709436 PMC: 11093927. DOI: 10.1007/s40119-024-00366-5.